SCHEMBL20028060

SCHEMBL20028060

Cc1cc(C(=O)O)n(-c2ccc(CNC(=O)Cc3ccccc3)cc2)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.60
ALDH1A1 P00352 6/20 0.52
LMNA P02545 2/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
RAB9A P51151 1/20 0.50
NPC1 O15118 1/20 0.50
GAA P10253 1/20 0.50
POLB P06746 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
MALT1 Q9UDY8 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
ERCC1 P07992 1/20 0.48
ERCC4 Q92889 1/20 0.48
P2RX7 Q99572 2/20 0.47
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20028059 0.90 MAPT (0.57) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL20028049 0.90 MAPT (0.54) MAPTALDH1A1GAASMN1; SMN2ERCC1
SCHEMBL22896940 0.89 MAPT (0.58) MAPTALDH1A1LMNAL3MBTL1MALT1
SCHEMBL22897209 0.85 MAPT (0.68) MAPTALDH1A1KMT2AGAAHDAC1
SCHEMBL20028203 0.84 MAPT (0.60) MAPTALDH1A1KMT2ARAB9APOLB
SCHEMBL22896513 0.83 MAPT (0.57) MAPTALDH1A1L3MBTL1HDAC3HDAC1
SCHEMBL20028526 0.82 MAPT (0.58) MAPTALDH1A1L3MBTL1
SCHEMBL21854080 0.81 MAPT (0.52) MAPTALDH1A1LMNA
SCHEMBL20027970 0.81 MAPT (0.52) MAPTALDH1A1LMNA
SCHEMBL20027616 0.80 MAPT (0.56) MAPTALDH1A1LMNAKMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339130-B1 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2022-05-24 US disclosed
US-10934261-B2 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2021-03-02 US disclosed
US-10894776-B2 2021-01-19 US disclosed
WO-2018064119-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPEUTICS, INC. (US) 2018-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934261-B2 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 MAPT 562/4885ALDH1A1 4193/4885LMNA 1415/4885
US-10894776-B2 CAPNS1, CAPN9, CAPN2 MAPT 330/4885ALDH1A1 4421/4885LMNA 1105/4885
US-11339130-B1 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 MAPT 562/4885ALDH1A1 4193/4885LMNA 1415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.